Maria Angeliki Toli
YOU?
Author Swipe
View article: Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study
Prognostic significance of tumour Ki-67 dynamics during neoadjuvant treatment in patients with breast cancer: a population-based cohort study Open
View article: The eHealtHeart Mobile Application for Managing Cardiac Toxicity in Patients with Breast Cancer: Preliminary Results From the CARDIOCARE Multicenter Study (Preprint)
The eHealtHeart Mobile Application for Managing Cardiac Toxicity in Patients with Breast Cancer: Preliminary Results From the CARDIOCARE Multicenter Study (Preprint) Open
BACKGROUND Breast cancer treatments can cause cardiotoxicity, particularly among elderly patients with comorbidities and frailty. This dual burden poses complex clinical challenges, including increased risk of cardiac complications, reduc…
View article: Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma
Pathologist-Read vs AI-Driven Assessment of Tumor-Infiltrating Lymphocytes in Melanoma Open
Importance Tumor-infiltrating lymphocytes (TILs) are a provocative biomarker in melanoma, influencing diagnosis, prognosis, and immunotherapy outcomes; however, traditional pathologist-read TIL assessment on hematoxylin and eosin–stained s…
View article: 73P Prognostic value of the relative change of Ki-67 during neoadjuvant chemotherapy for triple-negative breast cancer: A population-based study
73P Prognostic value of the relative change of Ki-67 during neoadjuvant chemotherapy for triple-negative breast cancer: A population-based study Open
View article: 145P A proteomics pilot study in the PREDIX HER2 breast cancer trial to identify novel biomarkers related to anti-HER2-therapy cardiotoxicity
145P A proteomics pilot study in the PREDIX HER2 breast cancer trial to identify novel biomarkers related to anti-HER2-therapy cardiotoxicity Open
View article: Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study
Prognosis After Pathologic Complete Response to Neoadjuvant Therapy in Early-Stage Breast Cancer: A Population-Based Study Open
Background: Pathologic complete response (pCR) following neoadjuvant chemotherapy (NACT) for early-stage breast cancer is prognostic, but not the sole surrogate marker for long-term outcome at a trial level, given that recurrence risk pers…
View article: A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression
A population-based study on trajectories of HER2 status during neoadjuvant chemotherapy for early breast cancer and metastatic progression Open
Background This study aimed to investigate the distribution and changes of HER2 status in untreated tumours, in residual disease and in metastasis, and their long-term prognostic implications. Methods This is a population-based cohort stud…
View article: 144P Factors affecting long term outcomes in patients with pathologic complete response after neoadjuvant chemotherapy for early breast cancer: A population-based study
144P Factors affecting long term outcomes in patients with pathologic complete response after neoadjuvant chemotherapy for early breast cancer: A population-based study Open
Pathologic complete response (pCR) following neoadjuvant chemotherapy (NACT) for early breast cancer is strongly prognostic. However, pCR is not a surrogate marker for long-term outcome at a trial level. Here, we aimed to investigate which…